HAEM5:Myelodysplastic neoplasm with biallelic TP53 inactivation: Difference between revisions
Bailey.Glen (talk | contribs) No edit summary |
Bailey.Glen (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Myelodysplastic neoplasm with biallelic TP53 inactivation}} | {{DISPLAYTITLE:Myelodysplastic neoplasm with biallelic TP53 inactivation}} | ||
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]] | [[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]] | ||
==Primary Author(s)*== | ==Primary Author(s)*== | ||
| Line 134: | Line 134: | ||
|'''Notes''' | |'''Notes''' | ||
|- | |- | ||
|EXAMPLE t(9;22)(q34;q11.2) | |<span class="blue-text">EXAMPLE:</span> t(9;22)(q34;q11.2) | ||
|EXAMPLE 3'ABL1 / 5'BCR | |<span class="blue-text">EXAMPLE:</span> 3'ABL1 / 5'BCR | ||
|EXAMPLE der(22) | |<span class="blue-text">EXAMPLE:</span> der(22) | ||
|EXAMPLE 20% (COSMIC) | |<span class="blue-text">EXAMPLE:</span> 20% (COSMIC) | ||
EXAMPLE 30% (add reference) | <span class="blue-text">EXAMPLE:</span> 30% (add reference) | ||
|Yes | |Yes | ||
|No | |No | ||
|Yes | |Yes | ||
|EXAMPLE | |<span class="blue-text">EXAMPLE:</span> | ||
The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). | The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). | ||